ATE473997T1 - Zur bildung von partikeln fähiges hbv-precore- protein - Google Patents

Zur bildung von partikeln fähiges hbv-precore- protein

Info

Publication number
ATE473997T1
ATE473997T1 AT03794268T AT03794268T ATE473997T1 AT E473997 T1 ATE473997 T1 AT E473997T1 AT 03794268 T AT03794268 T AT 03794268T AT 03794268 T AT03794268 T AT 03794268T AT E473997 T1 ATE473997 T1 AT E473997T1
Authority
AT
Austria
Prior art keywords
precore protein
hbv precore
particles
hbv
form particles
Prior art date
Application number
AT03794268T
Other languages
English (en)
Inventor
Noboru Maki
Tatsuji Kimura
Shintaro Yagi
Original Assignee
Advanced Life Science Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Life Science Inst Inc filed Critical Advanced Life Science Inst Inc
Application granted granted Critical
Publication of ATE473997T1 publication Critical patent/ATE473997T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
AT03794268T 2002-09-06 2003-09-05 Zur bildung von partikeln fähiges hbv-precore- protein ATE473997T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002261666 2002-09-06
PCT/JP2003/011389 WO2004022585A1 (ja) 2002-09-06 2003-09-05 粒子形成能を有するhbvプレコア蛋白質

Publications (1)

Publication Number Publication Date
ATE473997T1 true ATE473997T1 (de) 2010-07-15

Family

ID=31973137

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03794268T ATE473997T1 (de) 2002-09-06 2003-09-05 Zur bildung von partikeln fähiges hbv-precore- protein

Country Status (11)

Country Link
US (2) US7713532B2 (de)
EP (1) EP1535927B1 (de)
JP (1) JP4459054B2 (de)
KR (1) KR101093783B1 (de)
CN (1) CN100547001C (de)
AT (1) ATE473997T1 (de)
AU (1) AU2003261977A1 (de)
CA (1) CA2497972C (de)
DE (1) DE60333370D1 (de)
ES (1) ES2344737T3 (de)
WO (1) WO2004022585A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4386660B2 (ja) * 2003-03-25 2009-12-16 株式会社先端生命科学研究所 Ｈｂｖ−ｒｎａを含むｈｂｖ粒子
EP1765990A4 (de) * 2004-05-19 2008-07-09 Melbourne Health Therapeutische, prophylaktische und diagnostische agentien gegen hepatitis b
DE602005025626D1 (de) * 2004-05-19 2011-02-10 Advanced Life Science Inst Inc Verfahren zum nachweis von hepatitis-b-virus
WO2008053900A1 (fr) * 2006-10-30 2008-05-08 Advanced Life Science Institute, Inc. Procédé d'analyse immunologique à sensibilité élevée et réactif d'analyse immunologique pour le virus de l'hépatite b
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
CN103217533B (zh) 2012-01-21 2016-01-06 厦门大学 Anti-HBc定量检测方法及其在监控慢性乙肝患者病情发展和预测治疗疗效中的用途
JP2016507520A (ja) 2013-01-23 2016-03-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 安定化されたｂ型肝炎コアポリペプチド
WO2015133613A1 (ja) * 2014-03-07 2015-09-11 雅史 溝上 Ｂ型肝炎ウイルスレポーターベクター、ｂ型肝炎ウイルス様粒子及びそれを用いたｂ型肝炎治療薬のスクリーニング方法
JP7072213B2 (ja) * 2017-12-21 2022-05-20 国立研究開発法人理化学研究所 Ｂ型肝炎抗原タンパク質を標的としたイメージング用ｐｅｔプローブ
WO2020255425A1 (ja) * 2019-06-21 2020-12-24 国立研究開発法人理化学研究所 抗ｈｂｖ剤
CN113138276B (zh) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
CN113322302B (zh) * 2021-06-02 2023-08-11 重庆医科大学 一种hbv完整病毒颗粒的免疫捕获分子检测方法
CN113777329B (zh) * 2021-09-16 2023-07-18 何秋富 一种视黄醇结合蛋白测定试剂盒及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2358201A (en) 1999-12-03 2001-06-12 Innogenetics N.V. New hbv sequences
WO2001040278A2 (en) * 1999-12-06 2001-06-07 Zymogenetics, Inc. Human semaphorin zsmf-16
JP3847257B2 (ja) * 2000-08-11 2006-11-22 株式会社先端生命科学研究所 Ｈｂｖの検出又は測定方法

Also Published As

Publication number Publication date
US20060166187A1 (en) 2006-07-27
JP4459054B2 (ja) 2010-04-28
CA2497972C (en) 2016-04-26
HK1081207A1 (zh) 2006-05-12
EP1535927B1 (de) 2010-07-14
EP1535927A4 (de) 2006-06-21
DE60333370D1 (de) 2010-08-26
KR101093783B1 (ko) 2011-12-19
WO2004022585A1 (ja) 2004-03-18
US8383333B2 (en) 2013-02-26
US20100285444A1 (en) 2010-11-11
KR20050053636A (ko) 2005-06-08
US7713532B2 (en) 2010-05-11
CN1694898A (zh) 2005-11-09
AU2003261977A1 (en) 2004-03-29
ES2344737T3 (es) 2010-09-06
CN100547001C (zh) 2009-10-07
CA2497972A1 (en) 2004-03-18
EP1535927A1 (de) 2005-06-01
JPWO2004022585A1 (ja) 2005-12-22

Similar Documents

Publication Publication Date Title
ATE473997T1 (de) Zur bildung von partikeln fähiges hbv-precore- protein
EA200401064A1 (ru) Вирусоподобные частицы из вируса папилломы человека
PH12021551458A1 (en) Antibodies that neutralize hepatitis b virus and uses thereof
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
EA200300270A1 (ru) ИММУНОГЕННЫЕ ХИМЕРНЫЕ ЧАСТИЦЫ НВс, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ
DE60234085D1 (de) Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor
WO2008009652A3 (en) Vaccines for malaria
DE60123042D1 (de) L-fmau zur behandlung von hepatitis-delta-virus-infizierung
DE69922834D1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
ATE534729T1 (de) Hepatitis-b-virus-dna-polymerase und oberflächenantigen-varianten und methoden iher verwendung
ATE534666T1 (de) Antikörper gegen den hepatitis c-virus e1e2 komplex und pharmazeutische zusammensetzungen
ATE312846T1 (de) Monoklonale antikörper gegen hepatitis b virus
ATE552264T1 (de) Neue oberflächenprotein- (hbsag-) variante des hepatitis b virus
DE602006014720D1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
DE60327544D1 (de) Gentechnisch hergestelltes p30-antigen, verbesserter antigen-cocktail und verwendungen davon
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra
DE69814884D1 (de) Hepatitis b virale polypeptide
TW200510545A (en) HBV pre-core protein having particle-forming ability
TR200201954T2 (tr) Viral hastalıklar için tıbbi maddeler.
ATE526035T1 (de) Tollwut-impfstoff
RU2004104357A (ru) Вакцинный состав, потенцированный комбинацией днк и антигена

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties